Improvement in NYHA Functional Class 4 Congestive Heart Failure Patients with Nifedipine: A Hemodynamic Evaluation

1988 ◽  
Vol 295 (3) ◽  
pp. 188-192 ◽  
Author(s):  
Stephen C. Vlay ◽  
Linda Olson
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Functional Class ◽  
Heart Failure Patients ◽  
Nyha Functional Class ◽  
Hemodynamic Evaluation

scholarly journals Inflammatory Biomarkers in Refractory Congestive Heart Failure Patients Treated with Peritoneal Dialysis

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Margarita Kunin ◽  
Vered Carmon ◽  
Michael Arad ◽  
Nomy Levin-Iaina ◽  
Dov Freimark ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Peritoneal Dialysis ◽  
Inflammatory Cytokines ◽  
Protein A ◽  
Functional Class ◽  
Dialysis Treatment ◽  
Heart Failure Patients ◽  
Reactive Protein ◽  
Plasma Marker

Proinflammatory cytokines play a pathogenic role in congestive heart failure. In this study, the effect of peritoneal dialysis treatment on inflammatory cytokines levels in refractory congestive heart failure patients was investigated. During the treatment, the patients reached a well-tolerated edema-free state and demonstrated significant improvement in NYHA functional class. Brain natriuretic peptide decreased significantly after 3 months of treatment and remained stable at 6 months. C-reactive protein, a plasma marker of inflammation, decreased significantly following the treatment. Circulating inflammatory cytokines TNF-αand IL-6 decreased significantly after 3 months of peritoneal dialysis treatment and remained low at 6 months. The reduction in circulating inflammatory cytokines levels may be partly responsible for the efficacy of peritoneal dialysis for refractory congestive heart failure.

Medical Management Guided by Pulmonary Artery Pressures in NYHA Functional Class III Heart Failure Patients

2011 ◽  
Vol 17 (8) ◽  
pp. S93 ◽  
Author(s):  
Maria Rosa Costanzo ◽  
William T. Abraham ◽  
Philip B. Adamson ◽  
Pam A. Cowart ◽  
Kevin M. Corcoran ◽  
...  
Keyword(s):  
Heart Failure ◽  
Pulmonary Artery ◽  
Medical Management ◽  
Functional Class ◽  
Class Iii ◽  
Heart Failure Patients ◽  
Nyha Functional Class

TORASEMIDE FOR THE TREATMENT OF HEART FAILURE

2021 ◽  
pp. 27-30
Author(s):  
Harshawardhan Dhanraj Ramteke ◽  
Roshan Rajesh Menon
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Loop Diuretic ◽  
Symptomatic Relief ◽  
Left Ventricular ◽  
Functional Class ◽  
Line Treatment ◽  
Pharmacological Activities ◽  
Nyha Functional Class

Diuretics play a major role in the rst line treatment for the Congestive Heart Failure (CHF). These diuretics are currently and majorly used for symptomatic relief. Torasemide, a loop diuretic, is a newly developed loop diuretic, which has a longer half-life, longer duration for action, and higher bioavailability as compared to the other loop diuretics like furosemide. Torasemide, also works more effectively for the anti-aldosterone effect and vasorelaxation effect. Several studies have also suggested that torasemide has superior pharmacokinetics and pharmacological activities than that of furosemide. Results of several studies state that torasemide helps in improving the left ventricular function, reduces the mortality, as well as the frequency and duration of heart failure. Torasemide also improves the quality of life, tolerance and NYHA functional class in patients suffering from CHF. Based on these results, torasemide appears to be a promising loop diuretic for the rst line treatment and for better management of the patients with CHF. In this review, we provide a panorama of existing knowledge on the properties of torasemide, aimed at using it as a rst line of treatment for the patients in Congestive Heart Failure (CHF).

scholarly journals A simple nomogram to predict contrast-induced acute kidney injury in patients with congestive heart failure undergoing coronary angiography

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
L Lei ◽  
Y He ◽  
Z Guo ◽  
B Liu ◽  
J Liu ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Acute Kidney Injury ◽  
Coronary Angiography ◽  
Prediction Models ◽  
Validation Cohort ◽  
Kidney Injury ◽  
Class Ii ◽  
Functional Class ◽  
Killip Class

Abstract Background Patients with congestive heart failure (CHF) are vulnerable to contrast-induced acute kidney injury (CI-AKI), but few prediction models are currently available. Objectives We aimed to establish a simple nomogram for CI-AKI risk assessment for patients with CHF undergoing coronary angiography. Methods A total of 1876 consecutive patients with CHF (defined as New York Heart Association functional class II-IV or Killip class II-IV) were enrolled and randomly (2:1) assigned to a development cohort and a validation cohort. The endpoint was CI-AKI defined as serum creatinine elevation of ≥0.3 mg/dL or 50% from baseline within the first 48–72 hours following the procedure. Predictors for the nomogram were selected by multivariable logistic regression with a stepwise approach. The discriminative power was assessed using the area under the receiver operating characteristic (ROC) curve and was compared with the classic Mehran score in the validation cohort. Calibration was assessed using the Hosmer–Lemeshow test and 1000 bootstrap samples. Results The incidence of CI-AKI was 9.06% (n=170) in the total sample, 8.64% (n=109) in the development cohort and 9.92% (n=61) in the validation cohort (p=0.367). The simple nomogram including four predictors (age, intra-aortic balloon pump, acute myocardial infarction and chronic kidney disease) demonstrated a similar predictive power as the Mehran score (area under the curve: 0.80 vs 0.75, p=0.061), as well as a well-fitted calibration curve. Conclusions The present simple nomogram including four predictors is a simple and reliable tool to identify CHF patients at risk of CI-AKI, whereas further external validations are needed. Figure 1 Funding Acknowledgement Type of funding source: None

A Guide to Exercise for Congestive Heart Failure Patients

1998 ◽  
Vol 26 (8) ◽  
pp. 57-57
Author(s):  
James R. Clark ◽  
Carl Sherman ◽  
Nicholas A. DiNubile
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Heart Failure Patients
Sign in / Sign up

Export Citation Format

Share Document